A Phase 2 interventional study of DFD-03 Lotion, 0.1% and Tazorac Cream, 0.1% in Acne Vulgaris, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2020-08-17.
Sponsored by Dr. Reddy's Laboratories Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 138th largest by enrollment of the 354 interventional ones that give a count, is one of 23 that started in 2017, is one of 65 in phase 2, and was the 239th registered.
795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.
Browse Acne Vulgaris studies →20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sanofi Pasteur, a Sanofi Company · Sites in United States
Ages 18–45
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 23 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 70 across 676 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 354 interventional studies, 59 across the 19 observational. Of the 323 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
287 of 374 have an industry lead sponsor. The 10 most frequent:
Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.
Dr. Reddy's Laboratories Limited has 4 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
10 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT07946250BrocShot IncA Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 374 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Safety assessments will include the investigator's assessment of local cutaneous tolerance/application site reactions on the face, vital signs and adverse events.
A study for Subjects with mild to moderate facial acne vulgaris. Subjects will be randomized to treatment with either DFD-03 (tazarotene) Lotion 0.1%, Tazorac (tazarotene) Cream, 0.1%, Vehicle Lotion or Vehicle Cream. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Subjects will be instructed to treat the entire face.
Safety assessments will include the investigator's assessment of local cutaneous tolerance/application site reactions on the face, vital signs and adverse events. Urine pregnancy tests will be performed for all female subjects. A physical examination will be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment with the following products:
Topical acne treatments or other topical facial medication in the 14 days prior to Baseline Systemic and systemic acne treatments in the 30 days prior to Baseline Systemic retinoid use in the 180 days prior to Baseline Undertaken certain facial procedures such as chemical peel, laser treatment, photodynamic therapy, acne surgery, cryodestruction or chemodestruction, x-ray therapy, intralesional steroids, dermabrasion, or depilation (except eyebrow shaping) in 30 days prior to Baseline.
Treatment with a medication or procedure that, in the opinion of the investigator, would put the subject at unacceptable risk for participation in the study or may interfere with evaluations in the study.
Treatment with an product or device in 30 days prior to Baseline.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off
Drug: DFD-03 Lotion, 0.1%
Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours
Drug: Tazorac Cream, 0.1%
Vehicle Lotion to be applied twice daily for 1 minute and rinsed off
Drug: DFD-03 Vehicle Lotion 0%
Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours
Drug: Tazorac Vehicle Cream 0%
DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
Also known as: Tazarotene Lotion, 0.1%
Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
Also known as: Tazarotene Cream, 0.1%
Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
Also known as: Vehicle Lotion 0%
Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
Also known as: Vehicle Cream 0%
Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups
Frequency count of treatment emergent adverse events will be compared between DFD-03 Lotion and Tazorac Cream groups.
Time frame: Baseline to Week 12
| Milestone | DFD-03 Lotion, 0.1% | Tazorac Cream, 0.1% | DFD-03 Vehicle Lotion | Tazorac Vehicle Cream |
|---|---|---|---|---|
| Started | 54 | 49 | 26 | 26 |
| Completed | 54 | 49 | 26 | 26 |
| Not completed | 0 | 0 | 0 | 0 |
Frequency count of treatment emergent adverse events will be compared between DFD-03 Lotion and Tazorac Cream groups.
| Adverse Events | DFD-03 Lotion, 0.1% | Tazorac Cream, 0.1% | DFD-03 Vehicle Lotion | Tazorac Vehicle Cream |
|---|---|---|---|---|
| Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups | 73 | 81 | 14 | 15 |
Collected over Adverse events were collected from treatment initiation until study product treatment discontinuation (approximately 12 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DFD-03 Lotion, 0.1% | 0/54 (0%) | 0/54 (0%) | 22/54 (40.7%) |
| Tazorac Cream, 0.1% | 0/49 (0%) | 0/49 (0%) | 26/49 (53.1%) |
| Vehicle Lotion | 0/26 (0%) | 0/26 (0%) | 9/26 (34.6%) |
| Vehicle Cream | 0/26 (0%) | 0/26 (0%) | 11/26 (42.3%) |
| Event | DFD-03 Lotion, 0.1% | Tazorac Cream, 0.1% | Vehicle Lotion | Vehicle Cream |
|---|---|---|---|---|
| Application site drynessGeneral disorders | 18/54 | 17/49 | 2/26 | 3/26 |
| Application Site PainGeneral disorders | 14/54 | 13/49 | 1/26 | 1/26 |
| Application site exfoliationGeneral disorders | 14/54 | 12/49 | 2/26 | 3/26 |
| Application Site ErythemaGeneral disorders | 8/54 | 9/49 | 1/26 | 3/26 |
| Application Site PruritusGeneral disorders | 6/54 | 3/49 | 2/26 | 2/26 |
| Viral upper respiratory tract infectionInfections and infestations | 1/54 | 5/49 | 2/26 | 1/26 |
Safety Population - All subjects who received study product and provided any post-baseline safety information.
| Age, Categorical(Participants) | DFD-03 Lotion, 0.1% | Tazorac Cream, 0.1% | DFD-03 Vehicle Lotion | Tazorac Vehicle Cream | Total |
|---|---|---|---|---|---|
| <=18 years | 20 | 13 | 10 | 9 | 52 |
| Between 18 and 65 years | 34 | 36 | 16 | 17 | 103 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | DFD-03 Lotion, 0.1% | Tazorac Cream, 0.1% | DFD-03 Vehicle Lotion | Tazorac Vehicle Cream | Total |
|---|---|---|---|---|---|
| Mean | 21.9 ± 9.5 | 23.1 ± 8.9 | 22.0 ± 9.7 | 25.0 ± 10.5 | 22.8 ± 9.5 |
| Sex: Female, Male(Participants) | DFD-03 Lotion, 0.1% | Tazorac Cream, 0.1% | DFD-03 Vehicle Lotion | Tazorac Vehicle Cream | Total |
|---|---|---|---|---|---|
| Female | 25 | 27 | 12 | 12 | 76 |
| Male | 29 | 22 | 14 | 14 | 79 |
| Race (NIH/OMB)(Participants) | DFD-03 Lotion, 0.1% | Tazorac Cream, 0.1% | DFD-03 Vehicle Lotion | Tazorac Vehicle Cream | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 0 | 2 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 4 | 5 | 3 | 6 | 18 |
| White | 46 | 44 | 20 | 18 | 128 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | DFD-03 Lotion, 0.1% | Tazorac Cream, 0.1% | DFD-03 Vehicle Lotion | Tazorac Vehicle Cream | Total |
|---|---|---|---|---|---|
| United States | 54 | 49 | 26 | 26 | 155 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in May 2018, 8 months.
Results were first posted in Aug 2020, 2 years 2 months after primary completion. A results delay was requested in Sep 2019.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 8 months is below that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Reddy's Laboratories Limited →